Summary of ‘The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms’

摘要

This promotional supplement has been commissioned and funded by AstraZeneca UK Limited (“AstraZeneca”). AstraZeneca suggested the topics for the supplement, selected the authors, made honoraria payments to the authors, provided editorial comments and a full technical and medical review of the materials included within the supplement. Date of preparation: December 2020 / GB-25434